NAV
$35.03
AUM
$20.6M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +17.72% | +11.25% | +19.56% | +41.29% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 16.92% |
| 2 | UNH | UnitedHealth Group Inc | 7.30% |
| 3 | TMO | Thermo Fisher Scientific Inc | 4.43% |
| 4 | GILD | Gilead Sciences Inc | 4.30% |
| 5 | ABT | Abbott Laboratories | 3.32% |
| 6 | DHR | Danaher Corp | 2.90% |
| 7 | SYK | Stryker Corp | 2.39% |
| 8 | ELAN | Elanco Animal Health Inc | 2.12% |
| 9 | BSX | Boston Scientific Corp | 2.10% |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | 2.06% |
The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of health care companies. The manager defines health care companies as companies engaged in health care innovations, such as developing new and effective therapies; pharmaceuticals; biotechnology; life sciences tools and services; managed health care; and/or health care equipment, supplies, providers, services, distributors, and facilities. The fund is non-diversified.
Inception Date: 2025-06-11